An international evaluation of the cancer-preventive potential of nonsteroidal anti-inflammatory drugs.
An international evaluation of the cancer-preventive potential of nonsteroidal anti-inflammatory drugs.
复制标题
对非甾体类抗炎药预防癌症潜力的国际评估。
DOI：
--
复制
发表时间：
1997
期刊：
影响因子：
--
通讯作者：
Paul Kleihues
中科院分区：
文献类型：
--
作者：
Harri Vainio;G. Morgan;Paul Kleihues
IARC于1997年4月2日至8日在法国里昂召集了一个专家工作组，评估四种非类固醇抗炎药(阿司匹林、舒林酸、吡罗昔康和消炎痛)的癌症预防活性。设计、地点、人群和激励假设不同的阿司匹林的流行病学观察研究一致表明，定期使用阿司匹林可将结直肠癌的风险降低高达50%；然而，一项随机试验没有显示阿司匹林具有保护作用。化学预防活性的确凿证据通常需要来自适当设计的随机试验的数据。因此，阿司匹林预防人类结直肠癌的科学证据被认为是有限的。在动物模型中，有足够的证据表明阿司匹林可以预防癌症。阿司匹林和阿司匹林类药物可能有重要的副作用，其中最常见的是从消化不良到消化性溃疡等严重程度的胃肠紊乱。鉴于预防效果和不良副作用的风险仍存在不确定性，在建议广泛使用阿司匹林预防结直肠癌之前，需要详细考虑总的益处和毒性。舒林酸在减少家族性腺瘤性息肉病患者的腺瘤性息肉的数量和大小方面显示出希望。然而，还需要进一步的研究来确定是否以及在多大程度上降低了此类患者患结直肠癌的风险。在没有家族性腺瘤性息肉病的人中，没有足够的证据表明舒林酸具有预防癌症的活性。与阿司匹林和舒林酸相比，关于吡罗昔康和吲哚美辛的数据更少。尽管这些药物在实验动物模型中一直可以预防结直肠癌，但它们预防人类结直肠癌的证据被认为是不充分的。会议的结果，包括对未来研究的建议，将发表在IARC癌症预防手册的第一卷上。
The IARC convened a Working Group of experts in Lyon, France, on April 2-8, 1997 to evaluate the cancer-preventive activity of four nonsteroidal anti-inflammatory drugs (aspirin, sulindac, piroxicam, and indomethacin). Epidemiological observational studies of aspirin that differed in design, location, population, and motivating hypothesis have consistently shown that regular use lowers the risk for colorectal cancer by up to 50%; however, the one randomized trial did not show protection by aspirin. Definite evidence of chemopreventive activity normally requires data from appropriately designed randomized trials. The strength of the scientific evidence that aspirin prevents colorectal cancer in humans was thus considered to be limited. In animal models, there was sufficient evidence that aspirin prevented against cancer. Aspirin and aspirin-like drugs may have an important adverse side effects, the most frequent of which are gastrointestinal disturbances ranging in severity from dyspepsia to peptic ulcer. Given the remaining uncertainties in the preventive effect and the risk of adverse side effects, detailed consideration of the total benefits and of toxicity will be required before widespread use of aspirin for the prevention of colorectal cancer can be recommended. Sulindac shows promise in reducing the number and size of adenomatous polyps in patients with familial adenomatous polyposis. Further research is required, however, to determine whether and to what extent the risk for colorectal cancer in such patients is reduced. In people without familial adenomatous polyposis, there is inadequate evidence that sulindac has cancer-preventive activity. Fewer data were available on piroxicam and indomethacin than on aspirin and sulindac. Although these drugs consistently prevent colorectal cancers in experimental animal models, the evidence that they prevent colorectal cancer in humans was considered to be inadequate. The results of the meeting, including recommendations for future research, will be published as Volume 1 of the IARC Handbooks of Cancer Prevention.
登录
查看更多内容
影响因子：
56.9
作者：
MOSER, AR;PITOT, HC;DOVE, WF
通讯作者：
DOVE, WF
影响因子：
11.2
作者：
H. Sano;Y. Kawahito;R. Wilder;A. Hashiramoto;S. Mukai;K. Asai;S. Kimura;H. Kato;M. Kondo;T. Hla
通讯作者：
H. Sano;Y. Kawahito;R. Wilder;A. Hashiramoto;S. Mukai;K. Asai;S. Kimura;H. Kato;M. Kondo;T. Hla
影响因子：
29.4
作者：
DuBois, RN;Radhika, A;Entingh, AJ
通讯作者：
Entingh, AJ
过度表达前列腺素内过氧化物合酶 2 的细胞 G1 延迟。
影响因子：
11.2
作者：
DuBois,RN;Shao,J;Tsujii,M;Sheng,H;Beauchamp,RD
通讯作者：
Beauchamp,RD
非甾体抗炎药吡罗昔康对 Apc Min 小鼠模型中自发性肠腺瘤的化学预防。
DOI：
--
发表时间：
1996
期刊：
Cancer research.
影响因子：
--
作者：
Jacoby,RF;Marshall,DJ;Newton,MA;Novakovic,K;Tutsch,K;Cole,CE;Lubet,RA;Kelloff,GJ;Verma,A;Moser,AR;Dove,WF
通讯作者：
Dove,WF